Future Perspectives in Renal Cell Carcinoma (RCC)
Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.
Experience with Tivozanib in the 3rd Line Setting for Patients with RCC
Dr Thomas Hutson shares his experience with tivozanib in his practice and ways to counsel patients regarding treatment options in the third-line setting.
Tivozanib: Adverse Event Profile and How Toxicities are Managed
Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.
Clinical Implications of the TIVO-3 Trial
Dr Thomas Hutson reviews the TIVO-3 trial, including the most recent data that was presented at ASCO GU.
Treatment Options for Patients with Renal Cell Carcinoma (RCC)
An overview of the treatment options available for patients with renal cell carcinoma (RCC).
2 Clarke Drive Cranbury, NJ 08512